

Volition NuQ diagnostic platform for cancer is a success

06 November 2012 | News | By BioSpectrum Bureau

Volition NuQ diagnostic platform for cancer is a success



Singapore: VolitionRx revealed that its ongoing internal clinical trials of the NuQ diagnostic platform, has analyzed blood samples from 105 patients and was able to detect 76 percent of the patients with colon cancer, 96 percent of those with breast cancer, and 100 percent of patients with lung cancer. Volition tested all the patient samples for elevated nucleosome structures using one of its NuQ kits.

As announced in July, VolitionRx is currently moving through an independent 800-patient (expanded from the initial 400 patients) retrospective study on multiple cancer types, which is being carried out at Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany, and is expected to be completed by the end of this year.

Preliminary results from this study based on 62 healthy subjects, 20 patients with benign colon tumors and 35 patients with colorectal cancer are consistent with VolitionRx internal results and indicate that nucleosomics tests appear to differentiate cancer patients from patients with benign colon tumors as well as healthy patients.

Dr Jake Micallef, chief scientific officer, Belgian Volition, said that, "Our internal results are extremely promising, and are consistent with independent data from external studies. We are reaching out to several universities to collaborate on further trials of larger numbers of several single cancers, in order to have enough data to apply for European regulatory approval."

Dr Stefan Holdenrieder, Rheinische Friedrich-Wilhelms-Universität Bonn, who is the coordinator of the external trials, said that, "I am encouraged by the data coming out of Volition's internal trial and our study here in Bonn. Given the results we have thus far, we will begin collecting patient blood samples for the 2,000 patient prospective trial focusing on twenty prevalent cancers."